Skip to main content

ResMed Inc. (RMD) Stock Analysis

HoldModerate Confidence

Healthcare · Medical Instruments & Supplies

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and... Read more

$226.31+11.5% upside
Score 5.6/10Target $252.34Reward/Risk 1.9:1

TrendMatrix rates ResMed Inc. (RMD) as Hold with moderate confidence. The stock trades at $226.31 with +11.5% upside to the $252.34 price target. Overall score: 5.6/10 across 10 analysis dimensions. Reward/risk ratio: 1.9:1.

Passes 3/5 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

Val5.5Qual8.6Grw5.1Mom2.7Sent7.0Ins3.2Peer5.1Tech6.7Risk5.75.6OVERALL

Investment Thesis

+ V7 flight-to-quality bonus: +0.5 (Q=8.6 in RISK_OFF)
+ Sector modifier (): +1.2
+ Strong earnings beat streak (3/4)
- Negative momentum
- Below 200-day MA

Fundamentals

P/E (TTM)22.7
P/E (Fwd)18.8
Mkt Cap$33.5B
EV/EBITDA16.1
Profit Mgn27.5%
ROE25.7%
Rev Growth11.0%
Beta0.89
Dividend1.05%
Analysts25
Frequently Asked Questions
Is RMD stock a buy right now?

TrendMatrix rates ResMed Inc. (RMD) as Hold with moderate confidence. Score 5.6/10.

What is the RMD stock price target?

Take-profit target: $252.34 (+11.5% upside). Reward/risk ratio: 1.9:1. Stop-loss: $212.82.

What are the risks of investing in RMD?

Negative momentum; Below 200-day MA.

Is RMD overvalued or undervalued?

ResMed Inc. trades at a P/E of 22.7 (forward 18.8). TrendMatrix value score: 5.5/10. Verdict: Hold.

What do analysts say about RMD?

25 analysts cover RMD with a consensus score of 3.7/5. Average price target: $297.

What does ResMed Inc. do?ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to...

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Related stocks: RGEN (Repligen Corporation) · MMSI (Merit Medical Systems, Inc.) · SOLV (Solventum Corporation) · STVN (Stevanato Group S.p.A.) · NVST (Envista Holdings Corporation)
13 OVERSOLD
<20d<50d<200dDEATH CROSSSupp $219.40Res $260.22

Price Targets

$213
$252
Upside+11.5%
Reward/Risk1.9:1

Position Sizing

ConvictionNONE
Suggested %0.5%
Max %1%
RegimeRISK_OFF

Risk Alerts

! MOMENTUM:2.7<5.0
! DEATH_CROSS:HARD_BLOCK
FALLING KNIFETEMP HEADWINDSuitability: Moderate
Risk/Reward 2.3>=2.0
Insider activity: OK
No SEC red flags
Momentum 2.7<5.0
Death cross (50MA < 200MA)